Immunology of prostatic carcinoma-an overview.
The possibility of altering the course of prostatic cancer by immunologic means requires a clear understanding of the host-tumor relationship in this disease. Available data suggest that prostatic tumors contain both prostate-specific and tumor-specific antigens, although evidence on the latter is still debatable. Patients with prostatic cancer often show nonspecific depression of their cell-mediated immunocompetence, as do patients with many other forms of cancer. The question of whether prostatic cancers are immunogenic; that is, whether they elicit a specific immunologic response, remains unanswered.
D000135:Acid Phosphatase / Q000032:analysis; D000912:Antibodies, Neoplasm / Q000032:analysis; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000032:analysis; D002470:Cell Survival; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D008297:Male; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000276:immunology* / Q000628:therapy; D012882:Skin Tests
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000135:Acid Phosphatase